J

Johnson & Johnson

Makes prescription drugs and medical devices

Facilities Engineer - Compliance

Full-TimePosted on 10/20/2026Deadline 10/28/26
No salary listed
Mid
Bachelor's
Alajuela Province, Grecia, Costa Rica
In PersonPrimarily on-site; limited domestic or international travel may be required.
Manufacturing Quality & TestValidation, Compliance & Quality Systems

About the job

Requirements
  • A university bachelor's degree in mechanical, electrical, electromechanical, industrial, maintenance, chemical engineering, or another related engineering discipline.
  • Two to four years of related experience in Facilities Engineering, engineering compliance, quality systems, maintenance engineering, validation, manufacturing engineering, technical services, or another related engineering function.
  • Experience working within a regulated manufacturing environment.
  • Experience with quality systems, controlled documentation, engineering changes, risk assessments, investigations, qualification, validation, or compliance activities.
  • Advanced English proficiency, both written and verbal.
  • Practical knowledge of Facilities systems, utilities, infrastructure, and engineering processes within manufacturing environments.
  • Working knowledge of quality systems, Good Manufacturing Practice principles, controlled documentation, change management, risk assessment, and regulated manufacturing requirements.
  • Ability to evaluate technical information and potential operational, quality, and compliance impacts associated with engineering and Facilities activities.
  • Working knowledge of qualification, validation, investigation, and compliance principles applicable to engineering systems and processes.
  • Strong analytical, technical, and problem-solving skills.
  • Strong technical writing and documentation skills.
  • Ability to interpret engineering information, records, procedures, and technical requirements.
  • Strong attention to detail and commitment to documentation accuracy, traceability, and data integrity.
  • Effective communication, technical judgment, and cross-functional collaboration skills.
  • Ability to manage multiple priorities and work with moderate supervision in a dynamic manufacturing environment.
  • Continuous improvement, quality, and compliance mindset.
  • Proficiency with Microsoft Office applications and ability to work with applicable engineering, quality, and Facilities systems.
Responsibilities
  • Lead Facilities engineering compliance activities within assigned areas, ensuring Facilities systems, utilities, maintenance activities, engineering changes, and associated documentation meet applicable regulatory, quality, and Company requirements.
  • Own the development, review, revision, implementation, and lifecycle maintenance of Facilities procedures, forms, technical standards, records, and controlled documentation, ensuring technical content, traceability, and document control.
  • Lead and document technical risk assessments and quality impact evaluations for Facilities systems, projects, maintenance interventions, equipment failures, process changes, deviations, and operational events; determine appropriate compliance actions and escalation requirements.
  • Provide Facilities technical compliance assessment for engineering and change control activities, defining qualification, validation, documentation, testing, and implementation requirements needed to maintain the qualified or validated state of impacted systems.
  • Lead or provide Facilities technical expertise during investigations of deviations, nonconformances, system failures, recurring events, and compliance issues; support root cause determination and develop corrective, preventive, and remediation actions.
  • Coordinate and provide technical oversight of qualification, requalification, validation, commissioning, monitoring, and lifecycle compliance activities for applicable Facilities systems, critical utilities, cleanrooms, and controlled environments.
  • Evaluate maintenance strategies and interventions for critical Facilities assets and utilities to ensure preventive and corrective maintenance align with quality requirements, system criticality, qualification commitments, technical risk, and the established state of control.
  • Analyze Facilities compliance and engineering data, system performance, maintenance records, deviations, monitoring results, and recurring events to identify adverse trends, systemic gaps, emerging technical risks, and improvement opportunities.
  • Drive Facilities inspection readiness by assessing compliance status, identifying and remediating gaps, ensuring supporting evidence is available and accurate, and representing Facilities during applicable internal audits, external audits, inspections, and compliance assessments.
  • Provide compliance oversight for Facilities engineering projects, system modifications, equipment replacement, commissioning, and operational readiness to ensure regulatory and quality requirements are incorporated throughout planning, execution, turnover, and implementation.
  • Ensure Facilities records and technical data within the assigned scope are complete, accurate, attributable, traceable, and maintained according to applicable documentation and data integrity requirements.
  • Partner with Quality, Engineering, EHS, Manufacturing, Validation, Maintenance, and other functions to resolve complex Facilities compliance issues and ensure technical decisions consider product, process, regulatory, operational, and business impacts.
  • Serve as a Facilities compliance subject matter expert within assigned areas, providing technical guidance to Facilities personnel, service providers, contractors, and cross-functional teams on compliance requirements, engineering controls, and documentation expectations.
  • Identify compliance vulnerabilities and opportunities to strengthen Facilities quality systems, engineering practices, maintenance controls, documentation, qualification strategies, and inspection readiness; drive assigned remediation and continuous improvement initiatives to completion.
  • Escalate significant compliance gaps, technical risks, recurring failures, adverse trends, or conditions that may affect the qualified or validated state of Facilities systems, product or process quality, regulatory compliance, or continuity of operations to the appropriate management level.
  • Communicate business-related issues or opportunities to the next management level.
  • Follow Company guidelines related to Health, Safety, and Environmental practices, as applicable.
  • Ensure personal and Company compliance with applicable regulations, policies, and procedures.
  • Perform other duties as assigned.
  • Work primarily on-site at the Grecia, Alajuela, Costa Rica location; be available for limited domestic or international travel based on business needs.
Desired Qualifications
  • Experience with Facilities systems, utilities, infrastructure, maintenance activities, or related electromechanical systems is strongly preferred.
  • Agility Jumps.
  • Analytical reasoning.
  • Calibration procedures.
  • Chemical engineering.
  • Data savvy.
  • Equipment maintenance.
  • Facilities Engineering.
  • Facility management.
  • Lean Supply Chain Management.
  • Personal development.
  • Plant operations.
  • Proactive behavior.
  • Project recovery.
  • Project schedule.
  • Science, Technology, Engineering, and Math (STEM) application.
  • Supervision.
  • Technologically savvy.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.